Chronic graft-versus-host disease (cGVHD)
Conditions
Interventions
Observation group:none
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age = 12 years; 2.Patients diagnosed with chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation (referencing the 2014 NIH criteria); 3.Patients receiving CNI-class drugs during treatment, who have been added to besudil therapy, and who have undergone regular monitoring of CNI-class drug blood concentrations before and after dose adjustment. 4.Patients receiving CNI therapy, newly initiating bevacizumab treatment, and capable of regularly monitoring CNI blood concentrations; 5.The patient and their guardian consent to participate in this study and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Severe, uncontrollable complications; 2.Severe hepatic or renal impairment (Child-Pugh Class C or eGFR < 30 mL/min); 3.The patient has active leukemia or uncontrolled malignant tumors. 4.History of known severe allergic reactions to bevacizumab or CNI drugs; 5.The patient has severe mental or cognitive impairment, is unable to understand or comply with the treatment plan, and lacks the capacity to effectively sign an informed consent form. 6.The physician determined that the patient's condition was urgent and critical, making them unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood drug concentration/dose value (C/D);Blood drug concentration (C); | — |
Countries
China
Contacts
Public ContactHongliang Zhang
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed